Overview

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Metformin